PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1299130 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.0%
TTM net income YoY75.0%
TTM EPS YoY81.2%
Revenue 3-yr CAGR2.9%
Net income 3-yr CAGR—
Margins
Gross margin36.4%
Operating margin-83.5%
Net margin-82.5%
FCF margin-77.5%
EBITDA margin-77.4%
Returns
ROE-929.3%
ROA-16.7%
ROIC (approx.)—
Asset turnover0.20x
Leverage & solvency
Liabilities / assets104.4%
Debt / equity—
Current ratio4.92x
Interest coverage-18.15x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue3.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $40.56M | $39.01M | $37.18M | $44.65M | $38.44M | $39.77M | $37.15M | $39.22M |
| Cost of revenue | $27.09M | $26.37M | $24.34M | $28.08M | $22.54M | $25.08M | $38.52M | $29.17M |
| Gross profit | $13.47M | $12.64M | $12.84M | $16.57M | $15.90M | $14.68M | -$1.37M | $10.06M |
| R&D expense | $20.22M | $23.02M | $19.61M | $22.88M | $22.85M | $22.53M | $29.05M | $27.47M |
| SG&A expense | $29.42M | $33.39M | $31.15M | $34.05M | $31.10M | $36.17M | $40.17M | $41.64M |
| Operating income | -$37.00M | -$44.61M | -$8.36M | -$41.20M | -$38.88M | -$44.85M | -$428.93M | -$153.03M |
| Interest expense | $2.06M | $2.11M | $1.74M | $1.74M | $1.74M | $1.74M | $1.74M | $2.76M |
| Pretax income | -$37.58M | -$44.68M | -$8.09M | -$40.17M | -$37.62M | -$41.90M | -$426.38M | $2.69M |
| Income tax | $269,000 | $58,000 | $184,000 | $202,000 | $383,000 | $35,000 | -$302,000 | $316,000 |
| Net income | -$37.85M | -$44.74M | -$8.28M | -$40.37M | -$38.00M | -$41.93M | -$426.07M | $2.37M |
| EBITDA | -$34.54M | -$42.29M | -$6.16M | -$38.46M | -$36.42M | -$42.19M | -$423.80M | -$150.19M |
| EPS (basic) | -0.12 | -0.14 | -0.03 | — | -0.13 | -0.14 | -1.44 | — |
| EPS (diluted) | -0.12 | -0.14 | -0.03 | — | -0.13 | -0.14 | -1.44 | — |
| Weighted avg. shares (diluted) | 311.25M | 310.65M | 305.82M | — | 300.84M | 300.16M | 296.86M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $55.91M | $61.00M | $56.27M | $63.71M | $56.47M | $54.80M | $58.51M | $57.59M |
| Short-term investments | $143.51M | $175.87M | $219.69M | $215.80M | $242.19M | $259.93M | $284.60M | $334.56M |
| Receivables | $38.32M | $31.10M | $29.35M | $35.45M | $30.62M | $32.26M | $31.64M | $27.52M |
| Inventory | $60.28M | $61.08M | $51.02M | $49.28M | $53.15M | $53.84M | $54.01M | $58.76M |
| Current assets | $307.85M | $338.64M | $369.52M | $375.05M | $394.24M | $413.40M | $444.92M | $495.68M |
| PP&E, net | $29.28M | $26.97M | $24.38M | $24.15M | $22.13M | $23.10M | $24.79M | $30.50M |
| Goodwill | $317.76M | $317.76M | $317.76M | $317.76M | $317.76M | $317.76M | $317.76M | $317.76M |
| Intangibles | $12.16M | $13.08M | $14.10M | $15.12M | $16.14M | $17.16M | $18.18M | $389.57M |
| Total assets | $721.10M | $751.85M | $782.37M | $784.08M | $803.16M | $825.47M | $860.79M | $1.26B |
| Current liabilities | $66.59M | $68.81M | $65.36M | $72.83M | $63.21M | $59.75M | $66.60M | $66.30M |
| Short-term debt | — | — | — | — | — | — | — | $0 |
| Total liabilities | $782.48M | $785.06M | $780.00M | $778.73M | $767.07M | $763.98M | $769.15M | $753.85M |
| Shareholders' equity | -$61.38M | -$33.21M | $2.37M | $5.35M | $36.09M | $61.49M | $91.64M | $506.59M |
| Shares outstanding | 312.24M | 310.81M | 310.49M | 301.96M | 301.85M | 300.35M | 300.04M | 294.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$37.60M | -$35.58M | -$44.69M | -$19.07M | -$18.71M | -$29.38M | -$44.06M | -$30.65M |
| Capital expenditure | $988,000 | $1.55M | $3.04M | $861,000 | -$86,000 | $550,000 | $1.39M | $1.62M |
| Free cash flow | -$38.59M | -$37.14M | -$47.73M | -$19.93M | -$18.62M | -$29.93M | -$45.45M | -$32.27M |
| Investing cash flow | $31.11M | $40.07M | $35.86M | $26.03M | $18.90M | $25.28M | $45.23M | $58.24M |
| Financing cash flow | $1.46M | $255,000 | $1.44M | $0 | $1.47M | $0 | $1.96M | -$50.20M |
| Depreciation & amortization | $2.46M | $2.32M | $2.20M | $2.74M | $2.46M | $2.66M | $5.13M | $2.84M |
| Stock-based compensation | $8.54M | $9.26M | $4.46M | $9.59M | $10.98M | $11.89M | $9.20M | $16.03M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.